IFCT0401-bio phase II trial: Gefitinib administered as 1st-line in non-resectable adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC)—Predictive biomarkers of efficacy and survival

Marie Wislez,Martine Antoine,Virginie Poulot,Laurence Baudrin,Michèle Beau-Faller,Jean-François Morère,E. Brambilla,Marie Paule Lebitasy,Florence Coulet,J. Cadranel

IFCT0401-bio phase II trial: Gefitinib administered as 1st-line in non-resectable adenocarcinoma with bronchioloalveolar carcinoma features (ADC-BAC)—Predictive biomarkers of efficacy and survival

2008

Marie Wislez
Martine Antoine
Virginie Poulot
Laurence Baudrin
Michèle Beau-Faller
Jean-François Morère
E. Brambilla
Marie Paule Lebitasy
Florence Coulet
J. Cadranel

8071 Background: A prospective multicentric trial evaluated gefitinib as 1st-line in non-resectable ADC-BAC. Tissue samples were collected to identify biomarkers associated with disease control, PF...

Keywords:

Carcinoma
Biomarker (medicine)
Gefitinib
Pathology
Adenocarcinoma
Medicine
predictive biomarker
Internal medicine
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations